Conference abstract
Engineered erythrocytes as an anti-tumor therapy through induction of apoptosis or immune-checkpoint inhibition
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Rubius Therapeutics has built a platform for producing allogeneic Red Cell Therapeutics (RCTs), genetically modified red blood cells expanded ex vivo. Using lentiviral gene delivery, RCTs are able to harbor active intracellular as well as extracellular proteins, ranging from enzymes and cell targeting moieties to agonists and antibodies. RCTs represent a potentially transformational oncology platform, enabling multiple distinct modalities including tumor starvation, enhanced apoptotic signaling and immune checkpoint inhibition, among others. Further studies are underway to evaluate the ability of these and other RCTs to access and kill tumor cells in vitro and in vivo. These data support the development of RCTs as a novel class of therapeutic, enabling multiple modalities and mechanisms applicable to oncology and other indications.
Keywords
Subjects
Genetics & Molecular BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Stem Cell Research & Therapy
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Robert J Deans”
